SCHEDULE 13G/A: Streeterville Capital Reports Full Divestment of China SXT Pharmaceuticals Stake

Streeterville Capital LLC and its affiliates have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of China SXT Pharmaceuticals, Inc.

Summary

• This document is an Amendment No. 2 to a Schedule 13G filing by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife.
• The filing pertains to the common stock, $0.08 par value, of China SXT Pharmaceuticals, Inc. (CUSIP: G2161P140).
• As of the event date of January 17, 2025, the reporting persons collectively beneficially own 0.00 shares, representing 0.0% of the class.
• This indicates a complete divestment of their previously reported beneficial ownership in China SXT Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual regulatory disclosure of a change in beneficial ownership, indicating a complete divestment by the reporting entities. It does not contain information that inherently suggests positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Management Comments

• The reporting persons certified that, to the best of their knowledge and belief, the securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing is a standard regulatory disclosure required when a beneficial owner's stake in a publicly traded company changes, specifically when it falls below the 5% threshold or is completely divested. It provides transparency regarding institutional ownership changes within the pharmaceutical industry.

Stakeholder Impact

• Shareholders of China SXT Pharmaceuticals, Inc. may note the complete exit of Streeterville Capital LLC and its affiliates as beneficial owners, which could be interpreted as a change in institutional interest in the company.

Key Dates

Keywords

China SXT Pharmaceuticals, Schedule 13G, beneficial ownership, Streeterville Capital, divestment, common stock, SEC filing